Filters

Haemostasis

Showing results (41-50 of 1,359) with videos related to

Pageof 136
Sort By:
Haemostasis|September 1, 1996
Bleeding complications with new antithrombotics used in ischaemic heart diseaseA A Adgey
Haemostasis|September 1, 1996
Tissue plasminogen activator and plasminogen activator inhibitor status in Budd-Chiari syndromeS Dayal, H P Pati, M P Sharma
Haemostasis|January 1, 1996
Influence of the gamma-carboxyglutamic acid-rich domain and hydrophobic stack of factor VIIa on tissue factor bindingE Persson
Haemostasis|January 1, 1996
Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitorsJ M Lusher
Haemostasis|January 1, 1996
Recombinant factor VIIa in joint and muscle bleeding episodesR M Bech
Haemostasis|March 1, 1993
Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerationsP Ostergaard, O Nordfang, L C Petersen, et al.
Haemostasis|March 1, 1993
Cost/benefit aspects on thromboprophylaxisD Bergqvist, T Mätzsch
Haemostasis|March 1, 1993
Interactions of heparins in the vascular environmentJ Dawes
Haemostasis|January 1, 1977
Qualitative changes in fibrinogen following exposure to agents used for preparation of fibrin monomersF Brosstad, H C Godal
Haemostasis|March 9, 1999
Long-term prophylaxis in venous thromboembolism: LMWH or oral anticoagulation?S Schulman
Pageof 136

Showing results (41-50 of 1,359) with videos related to

Sort By:
Pageof 136
Haemostasis|September 1, 1996
Bleeding complications with new antithrombotics used in ischaemic heart diseaseA A Adgey
Haemostasis|September 1, 1996
Tissue plasminogen activator and plasminogen activator inhibitor status in Budd-Chiari syndromeS Dayal, H P Pati, M P Sharma
Haemostasis|January 1, 1996
Influence of the gamma-carboxyglutamic acid-rich domain and hydrophobic stack of factor VIIa on tissue factor bindingE Persson
Haemostasis|January 1, 1996
Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitorsJ M Lusher
Haemostasis|January 1, 1996
Recombinant factor VIIa in joint and muscle bleeding episodesR M Bech
Haemostasis|March 1, 1993
Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerationsP Ostergaard, O Nordfang, L C Petersen, et al.
Haemostasis|March 1, 1993
Cost/benefit aspects on thromboprophylaxisD Bergqvist, T Mätzsch
Haemostasis|March 1, 1993
Interactions of heparins in the vascular environmentJ Dawes
Haemostasis|January 1, 1977
Qualitative changes in fibrinogen following exposure to agents used for preparation of fibrin monomersF Brosstad, H C Godal
Haemostasis|March 9, 1999
Long-term prophylaxis in venous thromboembolism: LMWH or oral anticoagulation?S Schulman
Pageof 136
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us